Boehringer Ingelheim and Click Therapeutics have announced the launch of an expanded collaboration for development and commercialization of a second prescription digital therapeutic for those diagnosed with schizophrenia.
According to a release from Boehringer, the collaboration intends to produce a novel mobile application that combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes.
“We are very excited to expand our collaboration with Click